Eventide Asset Management’s Coherus Oncology CHRS Stock Holding History

Eventide Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-145,000	Closed	-$1.94M	–	142
2017 Q3	$1.94M	Hold	145,000	–	–	0.11%	106
2017 Q2	$2.08M	Hold	145,000	–	–	0.13%	96
2017 Q1	$3.07M	Hold	145,000	–	–	0.2%	85
2016 Q4	$4.08M	Hold	145,000	–	–	0.27%	76
2016 Q3	$3.88M	Hold	145,000	–	–	0.24%	75
2016 Q2	$2.45M	Hold	145,000	–	–	0.15%	94
2016 Q1	$3.08M	Buy	+145,000	New	+$2.38M	0.17%	89

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Eventide Asset Management's CHRS Position: Q4 2017 in Review

Eventide Asset Management sold out of Coherus Oncology (CHRS) in Q4 2017, closing a stake of 145,000 shares — an estimated $1.94M sold.

Eventide Asset Management first reported a position in CHRS in Q1 2016 and held it in 7 quarters. The position peaked at $4.08M in Q4 2016. 94 funds tracked by Wall St. Rank hold CHRS as of Q4 2017.

Eventide Asset Management reported no remaining Coherus Oncology position as of Q4 2017 after selling out during the quarter.
Eventide Asset Management sold 145,000 Coherus Oncology shares in Q4 2017, an estimated $1.94M.
Eventide Asset Management first reported a position in Coherus Oncology in Q1 2016 and held it in 7 quarters.
Eventide Asset Management's Coherus Oncology position peaked at $4.08M in Q4 2016.
94 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2017.

Based on Eventide Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.